nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—FKBP1A—esophageal cancer	0.686	0.931	CbGaD
Sirolimus—ABCB1—esophageal cancer	0.0505	0.0686	CbGaD
Sirolimus—EIF4E—digestive system—esophageal cancer	0.00273	0.0787	CbGeAlD
Sirolimus—Pimecrolimus—FKBP1A—esophageal cancer	0.00242	0.297	CrCbGaD
Sirolimus—Everolimus—FKBP1A—esophageal cancer	0.00242	0.297	CrCbGaD
Sirolimus—EIF4E—lung—esophageal cancer	0.00228	0.0657	CbGeAlD
Sirolimus—FGF2—bronchus—esophageal cancer	0.00216	0.0621	CbGeAlD
Sirolimus—FGF2—smooth muscle tissue—esophageal cancer	0.00211	0.0608	CbGeAlD
Sirolimus—MTOR—neck—esophageal cancer	0.00204	0.0588	CbGeAlD
Sirolimus—FGF2—trachea—esophageal cancer	0.00194	0.0558	CbGeAlD
Sirolimus—FKBP1A—neck—esophageal cancer	0.00184	0.0529	CbGeAlD
Sirolimus—Temsirolimus—FKBP1A—esophageal cancer	0.00163	0.201	CrCbGaD
Sirolimus—Tacrolimus—FKBP1A—esophageal cancer	0.00144	0.177	CrCbGaD
Sirolimus—FGF2—lung—esophageal cancer	0.00139	0.0401	CbGeAlD
Sirolimus—MTOR—epithelium—esophageal cancer	0.00139	0.04	CbGeAlD
Sirolimus—MTOR—smooth muscle tissue—esophageal cancer	0.00134	0.0386	CbGeAlD
Sirolimus—FKBP1A—epithelium—esophageal cancer	0.00125	0.036	CbGeAlD
Sirolimus—FKBP1A—bronchus—esophageal cancer	0.00123	0.0355	CbGeAlD
Sirolimus—FKBP1A—smooth muscle tissue—esophageal cancer	0.0012	0.0347	CbGeAlD
Sirolimus—FKBP1A—trachea—esophageal cancer	0.00111	0.0318	CbGeAlD
Sirolimus—MTOR—digestive system—esophageal cancer	0.00106	0.0305	CbGeAlD
Sirolimus—SLCO1B1—Methotrexate—esophageal cancer	0.001	0.579	CbGbCtD
Sirolimus—FGF2—lymph node—esophageal cancer	0.000952	0.0274	CbGeAlD
Sirolimus—FKBP1A—digestive system—esophageal cancer	0.000951	0.0274	CbGeAlD
Sirolimus—MTOR—lung—esophageal cancer	0.000883	0.0254	CbGeAlD
Sirolimus—SLC47A1—digestive system—esophageal cancer	0.000818	0.0235	CbGeAlD
Sirolimus—SLCO1B1—digestive system—esophageal cancer	0.000807	0.0232	CbGeAlD
Sirolimus—FKBP1A—lung—esophageal cancer	0.000794	0.0229	CbGeAlD
Sirolimus—SLC47A1—lung—esophageal cancer	0.000683	0.0197	CbGeAlD
Sirolimus—MTOR—lymph node—esophageal cancer	0.000604	0.0174	CbGeAlD
Sirolimus—FKBP1A—lymph node—esophageal cancer	0.000543	0.0156	CbGeAlD
Sirolimus—SLC47A1—lymph node—esophageal cancer	0.000467	0.0134	CbGeAlD
Sirolimus—ABCB1—Cisplatin—esophageal cancer	0.000443	0.255	CbGbCtD
Sirolimus—CYP3A5—digestive system—esophageal cancer	0.000414	0.0119	CbGeAlD
Sirolimus—CYP3A5—lung—esophageal cancer	0.000346	0.00996	CbGeAlD
Sirolimus—CYP3A4—digestive system—esophageal cancer	0.000311	0.00895	CbGeAlD
Sirolimus—ABCB1—epithelium—esophageal cancer	0.000289	0.00833	CbGeAlD
Sirolimus—ABCB1—Methotrexate—esophageal cancer	0.000287	0.166	CbGbCtD
Sirolimus—ABCB1—trachea—esophageal cancer	0.000256	0.00736	CbGeAlD
Sirolimus—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000241	0.00221	CcSEcCtD
Sirolimus—Atrial fibrillation—Capecitabine—esophageal cancer	0.00024	0.0022	CcSEcCtD
Sirolimus—Renal impairment—Capecitabine—esophageal cancer	0.000239	0.00219	CcSEcCtD
Sirolimus—Blood uric acid increased—Methotrexate—esophageal cancer	0.000237	0.00218	CcSEcCtD
Sirolimus—Pulmonary embolism—Methotrexate—esophageal cancer	0.000233	0.00214	CcSEcCtD
Sirolimus—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000233	0.00214	CcSEcCtD
Sirolimus—Stomatitis—Cisplatin—esophageal cancer	0.000231	0.00212	CcSEcCtD
Sirolimus—Conjunctivitis—Cisplatin—esophageal cancer	0.000231	0.00212	CcSEcCtD
Sirolimus—Hyponatraemia—Capecitabine—esophageal cancer	0.000228	0.00209	CcSEcCtD
Sirolimus—Osteoarthritis—Capecitabine—esophageal cancer	0.000227	0.00208	CcSEcCtD
Sirolimus—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000225	0.00206	CcSEcCtD
Sirolimus—ABCB1—digestive system—esophageal cancer	0.00022	0.00634	CbGeAlD
Sirolimus—Face oedema—Capecitabine—esophageal cancer	0.000219	0.00201	CcSEcCtD
Sirolimus—Urinary retention—Capecitabine—esophageal cancer	0.000216	0.00198	CcSEcCtD
Sirolimus—Mood swings—Capecitabine—esophageal cancer	0.000215	0.00197	CcSEcCtD
Sirolimus—Blood creatinine increased—Capecitabine—esophageal cancer	0.000213	0.00195	CcSEcCtD
Sirolimus—Dehydration—Capecitabine—esophageal cancer	0.000211	0.00194	CcSEcCtD
Sirolimus—Ecchymosis—Methotrexate—esophageal cancer	0.000211	0.00193	CcSEcCtD
Sirolimus—Mouth ulceration—Methotrexate—esophageal cancer	0.000211	0.00193	CcSEcCtD
Sirolimus—Urine output increased—Methotrexate—esophageal cancer	0.000211	0.00193	CcSEcCtD
Sirolimus—Neoplasm—Methotrexate—esophageal cancer	0.000211	0.00193	CcSEcCtD
Sirolimus—Bladder pain—Methotrexate—esophageal cancer	0.000211	0.00193	CcSEcCtD
Sirolimus—Urinary tract disorder—Cisplatin—esophageal cancer	0.00021	0.00193	CcSEcCtD
Sirolimus—Liver function test abnormal—Capecitabine—esophageal cancer	0.00021	0.00192	CcSEcCtD
Sirolimus—Connective tissue disorder—Cisplatin—esophageal cancer	0.000209	0.00192	CcSEcCtD
Sirolimus—Urethral disorder—Cisplatin—esophageal cancer	0.000209	0.00192	CcSEcCtD
Sirolimus—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000207	0.0019	CcSEcCtD
Sirolimus—Pulmonary oedema—Methotrexate—esophageal cancer	0.000207	0.0019	CcSEcCtD
Sirolimus—Hypokalaemia—Capecitabine—esophageal cancer	0.000207	0.0019	CcSEcCtD
Sirolimus—Visual impairment—Cisplatin—esophageal cancer	0.000205	0.00189	CcSEcCtD
Sirolimus—Breast disorder—Capecitabine—esophageal cancer	0.000205	0.00188	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000204	0.00188	CcSEcCtD
Sirolimus—Sepsis—Methotrexate—esophageal cancer	0.000202	0.00185	CcSEcCtD
Sirolimus—Gastritis—Capecitabine—esophageal cancer	0.000201	0.00184	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.0002	0.00184	CcSEcCtD
Sirolimus—Tinnitus—Cisplatin—esophageal cancer	0.000199	0.00182	CcSEcCtD
Sirolimus—Lymphadenopathy—Methotrexate—esophageal cancer	0.000198	0.00182	CcSEcCtD
Sirolimus—Cardiac disorder—Cisplatin—esophageal cancer	0.000198	0.00182	CcSEcCtD
Sirolimus—Abdominal distension—Capecitabine—esophageal cancer	0.000198	0.00181	CcSEcCtD
Sirolimus—Asthma—Capecitabine—esophageal cancer	0.000196	0.0018	CcSEcCtD
Sirolimus—Influenza—Capecitabine—esophageal cancer	0.000196	0.0018	CcSEcCtD
Sirolimus—Dysphagia—Capecitabine—esophageal cancer	0.000196	0.0018	CcSEcCtD
Sirolimus—Thrombophlebitis—Methotrexate—esophageal cancer	0.000195	0.00179	CcSEcCtD
Sirolimus—Diabetes mellitus—Methotrexate—esophageal cancer	0.000194	0.00178	CcSEcCtD
Sirolimus—Polyuria—Methotrexate—esophageal cancer	0.000193	0.00177	CcSEcCtD
Sirolimus—Immune system disorder—Cisplatin—esophageal cancer	0.000192	0.00177	CcSEcCtD
Sirolimus—Mediastinal disorder—Cisplatin—esophageal cancer	0.000192	0.00176	CcSEcCtD
Sirolimus—Bronchitis—Capecitabine—esophageal cancer	0.000189	0.00173	CcSEcCtD
Sirolimus—Hepatic failure—Methotrexate—esophageal cancer	0.000188	0.00173	CcSEcCtD
Sirolimus—Pancytopenia—Capecitabine—esophageal cancer	0.000186	0.00171	CcSEcCtD
Sirolimus—Malnutrition—Cisplatin—esophageal cancer	0.000186	0.0017	CcSEcCtD
Sirolimus—ABCB1—lung—esophageal cancer	0.000184	0.00529	CbGeAlD
Sirolimus—Dysuria—Capecitabine—esophageal cancer	0.000184	0.00168	CcSEcCtD
Sirolimus—Neutropenia—Capecitabine—esophageal cancer	0.000184	0.00168	CcSEcCtD
Sirolimus—Flatulence—Cisplatin—esophageal cancer	0.000183	0.00168	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000182	0.00167	CcSEcCtD
Sirolimus—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000179	0.00164	CcSEcCtD
Sirolimus—Weight increased—Capecitabine—esophageal cancer	0.000179	0.00164	CcSEcCtD
Sirolimus—Muscle spasms—Cisplatin—esophageal cancer	0.000178	0.00164	CcSEcCtD
Sirolimus—Weight decreased—Capecitabine—esophageal cancer	0.000178	0.00163	CcSEcCtD
Sirolimus—Hyperglycaemia—Capecitabine—esophageal cancer	0.000177	0.00163	CcSEcCtD
Sirolimus—Pneumonia—Capecitabine—esophageal cancer	0.000176	0.00162	CcSEcCtD
Sirolimus—Infestation NOS—Capecitabine—esophageal cancer	0.000175	0.00161	CcSEcCtD
Sirolimus—Infestation—Capecitabine—esophageal cancer	0.000175	0.00161	CcSEcCtD
Sirolimus—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000175	0.0016	CcSEcCtD
Sirolimus—Tremor—Cisplatin—esophageal cancer	0.000174	0.0016	CcSEcCtD
Sirolimus—Ill-defined disorder—Cisplatin—esophageal cancer	0.000172	0.00158	CcSEcCtD
Sirolimus—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000172	0.00157	CcSEcCtD
Sirolimus—Anaemia—Cisplatin—esophageal cancer	0.000171	0.00157	CcSEcCtD
Sirolimus—Stomatitis—Capecitabine—esophageal cancer	0.000171	0.00157	CcSEcCtD
Sirolimus—Urinary tract infection—Capecitabine—esophageal cancer	0.00017	0.00156	CcSEcCtD
Sirolimus—Conjunctivitis—Capecitabine—esophageal cancer	0.00017	0.00156	CcSEcCtD
Sirolimus—Osteoarthritis—Methotrexate—esophageal cancer	0.000169	0.00155	CcSEcCtD
Sirolimus—Malaise—Cisplatin—esophageal cancer	0.000167	0.00154	CcSEcCtD
Sirolimus—Haematuria—Capecitabine—esophageal cancer	0.000167	0.00153	CcSEcCtD
Sirolimus—Leukopenia—Cisplatin—esophageal cancer	0.000166	0.00152	CcSEcCtD
Sirolimus—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000165	0.00152	CcSEcCtD
Sirolimus—Epistaxis—Capecitabine—esophageal cancer	0.000165	0.00152	CcSEcCtD
Sirolimus—Mood swings—Methotrexate—esophageal cancer	0.00016	0.00147	CcSEcCtD
Sirolimus—Myalgia—Cisplatin—esophageal cancer	0.000158	0.00145	CcSEcCtD
Sirolimus—Haemoglobin—Capecitabine—esophageal cancer	0.000158	0.00145	CcSEcCtD
Sirolimus—Rhinitis—Capecitabine—esophageal cancer	0.000157	0.00145	CcSEcCtD
Sirolimus—Anxiety—Cisplatin—esophageal cancer	0.000157	0.00144	CcSEcCtD
Sirolimus—Haemorrhage—Capecitabine—esophageal cancer	0.000157	0.00144	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000157	0.00144	CcSEcCtD
Sirolimus—Hypoaesthesia—Capecitabine—esophageal cancer	0.000156	0.00143	CcSEcCtD
Sirolimus—Liver function test abnormal—Methotrexate—esophageal cancer	0.000156	0.00143	CcSEcCtD
Sirolimus—Discomfort—Cisplatin—esophageal cancer	0.000156	0.00143	CcSEcCtD
Sirolimus—Pharyngitis—Capecitabine—esophageal cancer	0.000156	0.00143	CcSEcCtD
Sirolimus—Urinary tract disorder—Capecitabine—esophageal cancer	0.000155	0.00142	CcSEcCtD
Sirolimus—Oedema peripheral—Capecitabine—esophageal cancer	0.000155	0.00142	CcSEcCtD
Sirolimus—Connective tissue disorder—Capecitabine—esophageal cancer	0.000154	0.00142	CcSEcCtD
Sirolimus—Urethral disorder—Capecitabine—esophageal cancer	0.000154	0.00141	CcSEcCtD
Sirolimus—Breast disorder—Methotrexate—esophageal cancer	0.000153	0.0014	CcSEcCtD
Sirolimus—Anaphylactic shock—Cisplatin—esophageal cancer	0.000151	0.00139	CcSEcCtD
Sirolimus—Oedema—Cisplatin—esophageal cancer	0.000151	0.00139	CcSEcCtD
Sirolimus—Visual impairment—Capecitabine—esophageal cancer	0.000151	0.00139	CcSEcCtD
Sirolimus—Infection—Cisplatin—esophageal cancer	0.00015	0.00138	CcSEcCtD
Sirolimus—Nervous system disorder—Cisplatin—esophageal cancer	0.000148	0.00136	CcSEcCtD
Sirolimus—Thrombocytopenia—Cisplatin—esophageal cancer	0.000148	0.00136	CcSEcCtD
Sirolimus—Tachycardia—Cisplatin—esophageal cancer	0.000148	0.00136	CcSEcCtD
Sirolimus—Skin disorder—Cisplatin—esophageal cancer	0.000147	0.00135	CcSEcCtD
Sirolimus—Tinnitus—Capecitabine—esophageal cancer	0.000146	0.00134	CcSEcCtD
Sirolimus—Hyperhidrosis—Cisplatin—esophageal cancer	0.000146	0.00134	CcSEcCtD
Sirolimus—Asthma—Methotrexate—esophageal cancer	0.000146	0.00134	CcSEcCtD
Sirolimus—Cardiac disorder—Capecitabine—esophageal cancer	0.000146	0.00134	CcSEcCtD
Sirolimus—Anorexia—Cisplatin—esophageal cancer	0.000144	0.00132	CcSEcCtD
Sirolimus—Pancreatitis—Methotrexate—esophageal cancer	0.000143	0.00131	CcSEcCtD
Sirolimus—Angiopathy—Capecitabine—esophageal cancer	0.000143	0.00131	CcSEcCtD
Sirolimus—Immune system disorder—Capecitabine—esophageal cancer	0.000142	0.0013	CcSEcCtD
Sirolimus—Mediastinal disorder—Capecitabine—esophageal cancer	0.000142	0.0013	CcSEcCtD
Sirolimus—Hypotension—Cisplatin—esophageal cancer	0.000141	0.0013	CcSEcCtD
Sirolimus—Chills—Capecitabine—esophageal cancer	0.000141	0.00129	CcSEcCtD
Sirolimus—Pancytopenia—Methotrexate—esophageal cancer	0.000139	0.00127	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000138	0.00127	CcSEcCtD
Sirolimus—Malnutrition—Capecitabine—esophageal cancer	0.000137	0.00126	CcSEcCtD
Sirolimus—Dysuria—Methotrexate—esophageal cancer	0.000137	0.00125	CcSEcCtD
Sirolimus—Neutropenia—Methotrexate—esophageal cancer	0.000137	0.00125	CcSEcCtD
Sirolimus—Paraesthesia—Cisplatin—esophageal cancer	0.000136	0.00125	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000136	0.00125	CcSEcCtD
Sirolimus—Dyspnoea—Cisplatin—esophageal cancer	0.000135	0.00124	CcSEcCtD
Sirolimus—Flatulence—Capecitabine—esophageal cancer	0.000135	0.00124	CcSEcCtD
Sirolimus—Erectile dysfunction—Methotrexate—esophageal cancer	0.000135	0.00124	CcSEcCtD
Sirolimus—Back pain—Capecitabine—esophageal cancer	0.000132	0.00121	CcSEcCtD
Sirolimus—Decreased appetite—Cisplatin—esophageal cancer	0.000132	0.00121	CcSEcCtD
Sirolimus—Muscle spasms—Capecitabine—esophageal cancer	0.000131	0.00121	CcSEcCtD
Sirolimus—Pneumonia—Methotrexate—esophageal cancer	0.000131	0.0012	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000131	0.0012	CcSEcCtD
Sirolimus—Infestation NOS—Methotrexate—esophageal cancer	0.00013	0.0012	CcSEcCtD
Sirolimus—Infestation—Methotrexate—esophageal cancer	0.00013	0.0012	CcSEcCtD
Sirolimus—Pain—Cisplatin—esophageal cancer	0.000129	0.00119	CcSEcCtD
Sirolimus—Tremor—Capecitabine—esophageal cancer	0.000128	0.00118	CcSEcCtD
Sirolimus—Stomatitis—Methotrexate—esophageal cancer	0.000127	0.00117	CcSEcCtD
Sirolimus—Ill-defined disorder—Capecitabine—esophageal cancer	0.000127	0.00116	CcSEcCtD
Sirolimus—Conjunctivitis—Methotrexate—esophageal cancer	0.000127	0.00116	CcSEcCtD
Sirolimus—Anaemia—Capecitabine—esophageal cancer	0.000126	0.00116	CcSEcCtD
Sirolimus—ABCB1—lymph node—esophageal cancer	0.000126	0.00362	CbGeAlD
Sirolimus—Sweating—Methotrexate—esophageal cancer	0.000125	0.00115	CcSEcCtD
Sirolimus—Feeling abnormal—Cisplatin—esophageal cancer	0.000125	0.00115	CcSEcCtD
Sirolimus—Haematuria—Methotrexate—esophageal cancer	0.000124	0.00114	CcSEcCtD
Sirolimus—Malaise—Capecitabine—esophageal cancer	0.000123	0.00113	CcSEcCtD
Sirolimus—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000123	0.00113	CcSEcCtD
Sirolimus—Epistaxis—Methotrexate—esophageal cancer	0.000123	0.00113	CcSEcCtD
Sirolimus—Syncope—Capecitabine—esophageal cancer	0.000123	0.00113	CcSEcCtD
Sirolimus—Leukopenia—Capecitabine—esophageal cancer	0.000122	0.00112	CcSEcCtD
Sirolimus—Palpitations—Capecitabine—esophageal cancer	0.000121	0.00111	CcSEcCtD
Sirolimus—Temsirolimus—ABCB1—esophageal cancer	0.00012	0.0148	CrCbGaD
Sirolimus—Loss of consciousness—Capecitabine—esophageal cancer	0.00012	0.0011	CcSEcCtD
Sirolimus—Body temperature increased—Cisplatin—esophageal cancer	0.00012	0.0011	CcSEcCtD
Sirolimus—Cough—Capecitabine—esophageal cancer	0.000119	0.0011	CcSEcCtD
Sirolimus—Hypertension—Capecitabine—esophageal cancer	0.000118	0.00108	CcSEcCtD
Sirolimus—Haemoglobin—Methotrexate—esophageal cancer	0.000118	0.00108	CcSEcCtD
Sirolimus—Haemorrhage—Methotrexate—esophageal cancer	0.000117	0.00107	CcSEcCtD
Sirolimus—Chest pain—Capecitabine—esophageal cancer	0.000116	0.00107	CcSEcCtD
Sirolimus—Arthralgia—Capecitabine—esophageal cancer	0.000116	0.00107	CcSEcCtD
Sirolimus—Myalgia—Capecitabine—esophageal cancer	0.000116	0.00107	CcSEcCtD
Sirolimus—Pharyngitis—Methotrexate—esophageal cancer	0.000116	0.00107	CcSEcCtD
Sirolimus—Anxiety—Capecitabine—esophageal cancer	0.000116	0.00106	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000116	0.00106	CcSEcCtD
Sirolimus—Urinary tract disorder—Methotrexate—esophageal cancer	0.000115	0.00106	CcSEcCtD
Sirolimus—Discomfort—Capecitabine—esophageal cancer	0.000115	0.00106	CcSEcCtD
Sirolimus—Urethral disorder—Methotrexate—esophageal cancer	0.000115	0.00105	CcSEcCtD
Sirolimus—Visual impairment—Methotrexate—esophageal cancer	0.000113	0.00103	CcSEcCtD
Sirolimus—Confusional state—Capecitabine—esophageal cancer	0.000113	0.00103	CcSEcCtD
Sirolimus—Oedema—Capecitabine—esophageal cancer	0.000112	0.00102	CcSEcCtD
Sirolimus—Hypersensitivity—Cisplatin—esophageal cancer	0.000112	0.00102	CcSEcCtD
Sirolimus—Infection—Capecitabine—esophageal cancer	0.000111	0.00102	CcSEcCtD
Sirolimus—Shock—Capecitabine—esophageal cancer	0.00011	0.00101	CcSEcCtD
Sirolimus—Nervous system disorder—Capecitabine—esophageal cancer	0.000109	0.001	CcSEcCtD
Sirolimus—Thrombocytopenia—Capecitabine—esophageal cancer	0.000109	0.001	CcSEcCtD
Sirolimus—Tinnitus—Methotrexate—esophageal cancer	0.000109	0.001	CcSEcCtD
Sirolimus—Tachycardia—Capecitabine—esophageal cancer	0.000109	0.001	CcSEcCtD
Sirolimus—Asthenia—Cisplatin—esophageal cancer	0.000109	0.000997	CcSEcCtD
Sirolimus—Cardiac disorder—Methotrexate—esophageal cancer	0.000109	0.000996	CcSEcCtD
Sirolimus—Skin disorder—Capecitabine—esophageal cancer	0.000108	0.000995	CcSEcCtD
Sirolimus—Hyperhidrosis—Capecitabine—esophageal cancer	0.000108	0.00099	CcSEcCtD
Sirolimus—Anorexia—Capecitabine—esophageal cancer	0.000106	0.000977	CcSEcCtD
Sirolimus—Angiopathy—Methotrexate—esophageal cancer	0.000106	0.000974	CcSEcCtD
Sirolimus—Tacrolimus—ABCB1—esophageal cancer	0.000106	0.013	CrCbGaD
Sirolimus—Immune system disorder—Methotrexate—esophageal cancer	0.000106	0.00097	CcSEcCtD
Sirolimus—Mediastinal disorder—Methotrexate—esophageal cancer	0.000105	0.000967	CcSEcCtD
Sirolimus—Chills—Methotrexate—esophageal cancer	0.000105	0.000963	CcSEcCtD
Sirolimus—Hypotension—Capecitabine—esophageal cancer	0.000104	0.000957	CcSEcCtD
Sirolimus—Diarrhoea—Cisplatin—esophageal cancer	0.000104	0.000951	CcSEcCtD
Sirolimus—Malnutrition—Methotrexate—esophageal cancer	0.000102	0.000934	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000102	0.000933	CcSEcCtD
Sirolimus—Insomnia—Capecitabine—esophageal cancer	0.000101	0.000927	CcSEcCtD
Sirolimus—Paraesthesia—Capecitabine—esophageal cancer	0.0001	0.00092	CcSEcCtD
Sirolimus—Dyspnoea—Capecitabine—esophageal cancer	9.95e-05	0.000913	CcSEcCtD
Sirolimus—Back pain—Methotrexate—esophageal cancer	9.85e-05	0.000904	CcSEcCtD
Sirolimus—Dyspepsia—Capecitabine—esophageal cancer	9.82e-05	0.000902	CcSEcCtD
Sirolimus—Decreased appetite—Capecitabine—esophageal cancer	9.7e-05	0.000891	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Capecitabine—esophageal cancer	9.64e-05	0.000884	CcSEcCtD
Sirolimus—Vomiting—Cisplatin—esophageal cancer	9.63e-05	0.000884	CcSEcCtD
Sirolimus—Rash—Cisplatin—esophageal cancer	9.55e-05	0.000876	CcSEcCtD
Sirolimus—Pain—Capecitabine—esophageal cancer	9.54e-05	0.000876	CcSEcCtD
Sirolimus—Constipation—Capecitabine—esophageal cancer	9.54e-05	0.000876	CcSEcCtD
Sirolimus—Dermatitis—Cisplatin—esophageal cancer	9.54e-05	0.000875	CcSEcCtD
Sirolimus—Ill-defined disorder—Methotrexate—esophageal cancer	9.45e-05	0.000867	CcSEcCtD
Sirolimus—Anaemia—Methotrexate—esophageal cancer	9.41e-05	0.000864	CcSEcCtD
Sirolimus—Feeling abnormal—Capecitabine—esophageal cancer	9.2e-05	0.000844	CcSEcCtD
Sirolimus—Malaise—Methotrexate—esophageal cancer	9.18e-05	0.000843	CcSEcCtD
Sirolimus—Gastrointestinal pain—Capecitabine—esophageal cancer	9.13e-05	0.000838	CcSEcCtD
Sirolimus—Leukopenia—Methotrexate—esophageal cancer	9.11e-05	0.000836	CcSEcCtD
Sirolimus—Nausea—Cisplatin—esophageal cancer	8.99e-05	0.000826	CcSEcCtD
Sirolimus—Cough—Methotrexate—esophageal cancer	8.88e-05	0.000815	CcSEcCtD
Sirolimus—Abdominal pain—Capecitabine—esophageal cancer	8.82e-05	0.00081	CcSEcCtD
Sirolimus—Body temperature increased—Capecitabine—esophageal cancer	8.82e-05	0.00081	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—esophageal cancer	8.67e-05	0.000796	CcSEcCtD
Sirolimus—Chest pain—Methotrexate—esophageal cancer	8.67e-05	0.000796	CcSEcCtD
Sirolimus—Myalgia—Methotrexate—esophageal cancer	8.67e-05	0.000796	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	8.61e-05	0.00079	CcSEcCtD
Sirolimus—Discomfort—Methotrexate—esophageal cancer	8.56e-05	0.000786	CcSEcCtD
Sirolimus—Confusional state—Methotrexate—esophageal cancer	8.38e-05	0.000769	CcSEcCtD
Sirolimus—Anaphylactic shock—Methotrexate—esophageal cancer	8.31e-05	0.000763	CcSEcCtD
Sirolimus—Infection—Methotrexate—esophageal cancer	8.25e-05	0.000758	CcSEcCtD
Sirolimus—Hypersensitivity—Capecitabine—esophageal cancer	8.22e-05	0.000755	CcSEcCtD
Sirolimus—Nervous system disorder—Methotrexate—esophageal cancer	8.15e-05	0.000748	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—esophageal cancer	8.13e-05	0.000747	CcSEcCtD
Sirolimus—Skin disorder—Methotrexate—esophageal cancer	8.07e-05	0.000741	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—esophageal cancer	8.03e-05	0.000737	CcSEcCtD
Sirolimus—Asthenia—Capecitabine—esophageal cancer	8.01e-05	0.000735	CcSEcCtD
Sirolimus—Anorexia—Methotrexate—esophageal cancer	7.92e-05	0.000727	CcSEcCtD
Sirolimus—Pruritus—Capecitabine—esophageal cancer	7.9e-05	0.000725	CcSEcCtD
Sirolimus—Hypotension—Methotrexate—esophageal cancer	7.76e-05	0.000713	CcSEcCtD
Sirolimus—Diarrhoea—Capecitabine—esophageal cancer	7.64e-05	0.000701	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methotrexate—esophageal cancer	7.57e-05	0.000695	CcSEcCtD
Sirolimus—Insomnia—Methotrexate—esophageal cancer	7.51e-05	0.00069	CcSEcCtD
Sirolimus—Paraesthesia—Methotrexate—esophageal cancer	7.46e-05	0.000685	CcSEcCtD
Sirolimus—Dyspnoea—Methotrexate—esophageal cancer	7.41e-05	0.00068	CcSEcCtD
Sirolimus—Somnolence—Methotrexate—esophageal cancer	7.39e-05	0.000678	CcSEcCtD
Sirolimus—Dizziness—Capecitabine—esophageal cancer	7.38e-05	0.000677	CcSEcCtD
Sirolimus—Dyspepsia—Methotrexate—esophageal cancer	7.31e-05	0.000671	CcSEcCtD
Sirolimus—Decreased appetite—Methotrexate—esophageal cancer	7.22e-05	0.000663	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Methotrexate—esophageal cancer	7.17e-05	0.000658	CcSEcCtD
Sirolimus—Pain—Methotrexate—esophageal cancer	7.1e-05	0.000652	CcSEcCtD
Sirolimus—Vomiting—Capecitabine—esophageal cancer	7.1e-05	0.000651	CcSEcCtD
Sirolimus—Rash—Capecitabine—esophageal cancer	7.04e-05	0.000646	CcSEcCtD
Sirolimus—Dermatitis—Capecitabine—esophageal cancer	7.03e-05	0.000645	CcSEcCtD
Sirolimus—Headache—Capecitabine—esophageal cancer	6.99e-05	0.000642	CcSEcCtD
Sirolimus—Feeling abnormal—Methotrexate—esophageal cancer	6.85e-05	0.000628	CcSEcCtD
Sirolimus—Gastrointestinal pain—Methotrexate—esophageal cancer	6.79e-05	0.000624	CcSEcCtD
Sirolimus—Nausea—Capecitabine—esophageal cancer	6.63e-05	0.000609	CcSEcCtD
Sirolimus—Body temperature increased—Methotrexate—esophageal cancer	6.57e-05	0.000603	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—esophageal cancer	6.57e-05	0.000603	CcSEcCtD
Sirolimus—Hypersensitivity—Methotrexate—esophageal cancer	6.12e-05	0.000562	CcSEcCtD
Sirolimus—Asthenia—Methotrexate—esophageal cancer	5.96e-05	0.000547	CcSEcCtD
Sirolimus—Pruritus—Methotrexate—esophageal cancer	5.88e-05	0.00054	CcSEcCtD
Sirolimus—Diarrhoea—Methotrexate—esophageal cancer	5.68e-05	0.000522	CcSEcCtD
Sirolimus—Dizziness—Methotrexate—esophageal cancer	5.49e-05	0.000504	CcSEcCtD
Sirolimus—Vomiting—Methotrexate—esophageal cancer	5.28e-05	0.000485	CcSEcCtD
Sirolimus—Rash—Methotrexate—esophageal cancer	5.24e-05	0.000481	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—esophageal cancer	5.23e-05	0.00048	CcSEcCtD
Sirolimus—Headache—Methotrexate—esophageal cancer	5.2e-05	0.000478	CcSEcCtD
Sirolimus—Nausea—Methotrexate—esophageal cancer	4.93e-05	0.000453	CcSEcCtD
Sirolimus—CYP3A5—Metabolism—TYMP—esophageal cancer	1.4e-05	0.000128	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—MYC—esophageal cancer	1.39e-05	0.000127	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ENO1—esophageal cancer	1.38e-05	0.000127	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS1—esophageal cancer	1.38e-05	0.000127	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.38e-05	0.000126	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HIF1A—esophageal cancer	1.37e-05	0.000125	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EGFR—esophageal cancer	1.37e-05	0.000125	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NOS3—esophageal cancer	1.37e-05	0.000125	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PSME2—esophageal cancer	1.36e-05	0.000125	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PSME1—esophageal cancer	1.36e-05	0.000125	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP26A1—esophageal cancer	1.36e-05	0.000124	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTT1—esophageal cancer	1.36e-05	0.000124	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CA2—esophageal cancer	1.35e-05	0.000124	CbGpPWpGaD
Sirolimus—FGF2—Disease—NOS2—esophageal cancer	1.35e-05	0.000123	CbGpPWpGaD
Sirolimus—MTOR—Disease—SMAD4—esophageal cancer	1.35e-05	0.000123	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—ERBB2—esophageal cancer	1.35e-05	0.000123	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFBR2—esophageal cancer	1.34e-05	0.000123	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP2A6—esophageal cancer	1.34e-05	0.000123	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—ERBB2—esophageal cancer	1.34e-05	0.000122	CbGpPWpGaD
Sirolimus—FGF2—Disease—NOTCH1—esophageal cancer	1.34e-05	0.000122	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PSME1—esophageal cancer	1.33e-05	0.000121	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PSME2—esophageal cancer	1.33e-05	0.000121	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALOX15—esophageal cancer	1.33e-05	0.000121	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ANXA1—esophageal cancer	1.32e-05	0.000121	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CASP8—esophageal cancer	1.32e-05	0.000121	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CREBBP—esophageal cancer	1.31e-05	0.00012	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KDR—esophageal cancer	1.31e-05	0.00012	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTGS2—esophageal cancer	1.31e-05	0.00012	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EGFR—esophageal cancer	1.31e-05	0.00012	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.29e-05	0.000118	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SST—esophageal cancer	1.28e-05	0.000117	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ERBB2—esophageal cancer	1.28e-05	0.000117	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ENO1—esophageal cancer	1.27e-05	0.000116	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS1—esophageal cancer	1.27e-05	0.000116	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SMAD4—esophageal cancer	1.27e-05	0.000116	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTO1—esophageal cancer	1.26e-05	0.000116	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TPI1—esophageal cancer	1.26e-05	0.000116	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ADH7—esophageal cancer	1.26e-05	0.000115	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PLCE1—esophageal cancer	1.26e-05	0.000115	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—EGFR—esophageal cancer	1.26e-05	0.000115	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PSME2—esophageal cancer	1.25e-05	0.000114	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PSME1—esophageal cancer	1.25e-05	0.000114	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GHRL—esophageal cancer	1.25e-05	0.000114	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOTCH3—esophageal cancer	1.25e-05	0.000114	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.25e-05	0.000114	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NOTCH1—esophageal cancer	1.24e-05	0.000113	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FBXW7—esophageal cancer	1.23e-05	0.000113	CbGpPWpGaD
Sirolimus—FGF2—Disease—CREBBP—esophageal cancer	1.21e-05	0.000111	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALDOB—esophageal cancer	1.21e-05	0.000111	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CDKN1A—esophageal cancer	1.2e-05	0.000109	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.19e-05	0.000109	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—PIK3CA—esophageal cancer	1.19e-05	0.000109	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.19e-05	0.000109	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP1B1—esophageal cancer	1.18e-05	0.000108	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GAPDH—esophageal cancer	1.17e-05	0.000107	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CRABP1—esophageal cancer	1.16e-05	0.000106	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CDKN1A—esophageal cancer	1.15e-05	0.000105	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CDKN1A—esophageal cancer	1.15e-05	0.000105	CbGpPWpGaD
Sirolimus—MTOR—Immune System—TLR4—esophageal cancer	1.14e-05	0.000104	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EP300—esophageal cancer	1.14e-05	0.000104	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—PIK3CA—esophageal cancer	1.14e-05	0.000104	CbGpPWpGaD
Sirolimus—FGF2—Immune System—BCL2—esophageal cancer	1.13e-05	0.000104	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCND1—esophageal cancer	1.13e-05	0.000103	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOTCH2—esophageal cancer	1.12e-05	0.000103	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CREBBP—esophageal cancer	1.12e-05	0.000102	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP19A1—esophageal cancer	1.11e-05	0.000101	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ADH1B—esophageal cancer	1.1e-05	0.000101	CbGpPWpGaD
Sirolimus—MTOR—Disease—HIF1A—esophageal cancer	1.1e-05	0.000101	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GNG7—esophageal cancer	1.1e-05	0.000101	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ERBB2—esophageal cancer	1.1e-05	0.000101	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CDKN1A—esophageal cancer	1.09e-05	0.0001	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—PIK3CA—esophageal cancer	1.09e-05	9.97e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EP300—esophageal cancer	1.09e-05	9.96e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—NOS3—esophageal cancer	1.09e-05	9.93e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP1B1—esophageal cancer	1.08e-05	9.88e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.08e-05	9.87e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.07e-05	9.81e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.07e-05	9.81e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TYMP—esophageal cancer	1.06e-05	9.65e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EP300—esophageal cancer	1.04e-05	9.51e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HIF1A—esophageal cancer	1.04e-05	9.5e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.04e-05	9.47e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALDH2—esophageal cancer	1.03e-05	9.42e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.03e-05	9.38e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP19A1—esophageal cancer	1.02e-05	9.29e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—ERBB2—esophageal cancer	1.02e-05	9.28e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.01e-05	9.26e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—HMOX1—esophageal cancer	1.01e-05	9.24e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NOS3—esophageal cancer	1e-05	9.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOS2—esophageal cancer	1e-05	9.16e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALOX15—esophageal cancer	1e-05	9.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFBR2—esophageal cancer	9.96e-06	9.11e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KDR—esophageal cancer	9.94e-06	9.09e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—esophageal cancer	9.93e-06	9.08e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOTCH1—esophageal cancer	9.93e-06	9.07e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	9.91e-06	9.06e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTT1—esophageal cancer	9.81e-06	8.96e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CASP8—esophageal cancer	9.79e-06	8.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CREBBP—esophageal cancer	9.75e-06	8.91e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—esophageal cancer	9.71e-06	8.88e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ABCB1—esophageal cancer	9.7e-06	8.86e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP2A6—esophageal cancer	9.69e-06	8.86e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTO1—esophageal cancer	9.54e-06	8.72e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TPI1—esophageal cancer	9.54e-06	8.72e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MYC—esophageal cancer	9.5e-06	8.68e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SMAD4—esophageal cancer	9.43e-06	8.62e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CDKN1A—esophageal cancer	9.4e-06	8.59e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ERBB2—esophageal cancer	9.38e-06	8.58e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NOTCH1—esophageal cancer	9.37e-06	8.56e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—esophageal cancer	9.33e-06	8.53e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—esophageal cancer	9.29e-06	8.49e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—HMOX1—esophageal cancer	9.27e-06	8.48e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ENO1—esophageal cancer	9.19e-06	8.4e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS1—esophageal cancer	9.19e-06	8.4e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALDOB—esophageal cancer	9.15e-06	8.36e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC10A2—esophageal cancer	9.12e-06	8.34e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CA1—esophageal cancer	9.12e-06	8.34e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—esophageal cancer	9.07e-06	8.29e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PSME2—esophageal cancer	9.05e-06	8.28e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PSME1—esophageal cancer	9.05e-06	8.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CREBBP—esophageal cancer	9e-06	8.23e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EP300—esophageal cancer	8.95e-06	8.18e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ABCB1—esophageal cancer	8.9e-06	8.14e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—esophageal cancer	8.87e-06	8.11e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GAPDH—esophageal cancer	8.81e-06	8.05e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	8.79e-06	8.04e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CRABP1—esophageal cancer	8.73e-06	7.98e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—CDKN1A—esophageal cancer	8.68e-06	7.93e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	8.5e-06	7.77e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CREBBP—esophageal cancer	8.49e-06	7.76e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PIK3CA—esophageal cancer	8.43e-06	7.71e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—BCL2—esophageal cancer	8.4e-06	7.68e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CA2—esophageal cancer	8.34e-06	7.63e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GNG7—esophageal cancer	8.3e-06	7.59e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—esophageal cancer	8.29e-06	7.58e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—EP300—esophageal cancer	8.26e-06	7.55e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB2—esophageal cancer	8.16e-06	7.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PIK3CA—esophageal cancer	8.1e-06	7.4e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PIK3CA—esophageal cancer	8.06e-06	7.37e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOS3—esophageal cancer	8.06e-06	7.37e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDKN1A—esophageal cancer	8.02e-06	7.33e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP1B1—esophageal cancer	7.81e-06	7.14e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALDH2—esophageal cancer	7.78e-06	7.11e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PLCE1—esophageal cancer	7.76e-06	7.09e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADH7—esophageal cancer	7.76e-06	7.09e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HIF1A—esophageal cancer	7.72e-06	7.05e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PIK3CA—esophageal cancer	7.7e-06	7.04e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EP300—esophageal cancer	7.63e-06	6.98e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—esophageal cancer	7.62e-06	6.97e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NOS3—esophageal cancer	7.6e-06	6.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB2—esophageal cancer	7.54e-06	6.89e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—esophageal cancer	7.45e-06	6.81e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTT1—esophageal cancer	7.4e-06	6.76e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KDR—esophageal cancer	7.38e-06	6.74e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—esophageal cancer	7.37e-06	6.74e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP19A1—esophageal cancer	7.35e-06	6.71e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.33e-06	6.7e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP2A6—esophageal cancer	7.31e-06	6.69e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—esophageal cancer	7.2e-06	6.58e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB2—esophageal cancer	7.11e-06	6.5e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—esophageal cancer	7.04e-06	6.43e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1A—esophageal cancer	6.98e-06	6.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOTCH1—esophageal cancer	6.95e-06	6.35e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ENO1—esophageal cancer	6.93e-06	6.34e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS1—esophageal cancer	6.93e-06	6.34e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	6.93e-06	6.33e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PSME2—esophageal cancer	6.83e-06	6.25e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PSME1—esophageal cancer	6.83e-06	6.25e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADH1B—esophageal cancer	6.8e-06	6.22e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HMOX1—esophageal cancer	6.7e-06	6.13e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—esophageal cancer	6.65e-06	6.08e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EP300—esophageal cancer	6.64e-06	6.07e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PIK3CA—esophageal cancer	6.62e-06	6.05e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—esophageal cancer	6.5e-06	5.95e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TYMP—esophageal cancer	6.5e-06	5.94e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CREBBP—esophageal cancer	6.48e-06	5.92e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1A—esophageal cancer	6.44e-06	5.89e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ABCB1—esophageal cancer	6.43e-06	5.88e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP26A1—esophageal cancer	6.32e-06	5.78e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CREBBP—esophageal cancer	6.3e-06	5.76e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—esophageal cancer	6.28e-06	5.74e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALOX15—esophageal cancer	6.16e-06	5.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EP300—esophageal cancer	6.13e-06	5.6e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PIK3CA—esophageal cancer	6.11e-06	5.58e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1A—esophageal cancer	6.08e-06	5.56e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CREBBP—esophageal cancer	5.95e-06	5.44e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP1B1—esophageal cancer	5.9e-06	5.39e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTO1—esophageal cancer	5.88e-06	5.37e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TPI1—esophageal cancer	5.88e-06	5.37e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—NOS3—esophageal cancer	5.8e-06	5.3e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EP300—esophageal cancer	5.78e-06	5.29e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—esophageal cancer	5.66e-06	5.17e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CA—esophageal cancer	5.65e-06	5.16e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOS3—esophageal cancer	5.64e-06	5.16e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALDOB—esophageal cancer	5.64e-06	5.15e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP19A1—esophageal cancer	5.54e-06	5.07e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—esophageal cancer	5.46e-06	4.99e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GAPDH—esophageal cancer	5.43e-06	4.96e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CRABP1—esophageal cancer	5.38e-06	4.92e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—esophageal cancer	5.34e-06	4.88e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—NOS3—esophageal cancer	5.33e-06	4.87e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—esophageal cancer	5.31e-06	4.85e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB2—esophageal cancer	5.28e-06	4.82e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—esophageal cancer	5.22e-06	4.78e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNG7—esophageal cancer	5.11e-06	4.68e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HMOX1—esophageal cancer	5.06e-06	4.62e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—esophageal cancer	5.04e-06	4.61e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—esophageal cancer	4.93e-06	4.51e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CA—esophageal cancer	4.91e-06	4.49e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—esophageal cancer	4.87e-06	4.45e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALDH2—esophageal cancer	4.79e-06	4.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—esophageal cancer	4.66e-06	4.26e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTT1—esophageal cancer	4.56e-06	4.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CA—esophageal cancer	4.53e-06	4.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1A—esophageal cancer	4.51e-06	4.12e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP2A6—esophageal cancer	4.51e-06	4.12e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—EP300—esophageal cancer	4.41e-06	4.04e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CREBBP—esophageal cancer	4.3e-06	3.93e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EP300—esophageal cancer	4.29e-06	3.92e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CA—esophageal cancer	4.28e-06	3.91e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.27e-06	3.9e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ENO1—esophageal cancer	4.27e-06	3.9e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PSME1—esophageal cancer	4.21e-06	3.85e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PSME2—esophageal cancer	4.21e-06	3.85e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—esophageal cancer	4.14e-06	3.78e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—EP300—esophageal cancer	4.05e-06	3.7e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NOS3—esophageal cancer	3.85e-06	3.52e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—esophageal cancer	3.74e-06	3.42e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—esophageal cancer	3.66e-06	3.34e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP1B1—esophageal cancer	3.63e-06	3.32e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—esophageal cancer	3.52e-06	3.22e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.41e-06	3.12e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CA—esophageal cancer	3.27e-06	2.98e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CREBBP—esophageal cancer	3.24e-06	2.97e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CA—esophageal cancer	3.17e-06	2.9e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.12e-06	2.85e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—esophageal cancer	3.07e-06	2.81e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CA—esophageal cancer	3e-06	2.74e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.99e-06	2.73e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—EP300—esophageal cancer	2.93e-06	2.68e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NOS3—esophageal cancer	2.9e-06	2.66e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—esophageal cancer	2.66e-06	2.43e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—EP300—esophageal cancer	2.21e-06	2.02e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CA—esophageal cancer	2.17e-06	1.98e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CREBBP—esophageal cancer	2e-06	1.83e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NOS3—esophageal cancer	1.79e-06	1.64e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.64e-06	1.5e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CA—esophageal cancer	1.63e-06	1.49e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—EP300—esophageal cancer	1.36e-06	1.24e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.01e-06	9.21e-06	CbGpPWpGaD
